Soleno Therapeutics Inc.
SLNO:NASDAQ
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.
Streetwise Company Fact Sheet2025/5/9 0:12:46
(SLNO:NASDAQ)
Analyst coverage
| Oppenheimer & Co. — Dr. Leland Gershell |
Newsletter coverage
| — |
Streetwise Reports Articles
| 03/25/2025 - View Article |
| 01/05/2024 - View Article |
| 10/12/2023 - View Article |
| 10/09/2023 - View Article |
| 06/29/2023 - View Article |
Streetwise - Soleno Therapeutics Inc. Ownership Overview*
Soleno Therapeutics Inc. (SLNO:NASDAQ)
*Share Structure as of 3/25/2025
© 2025 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
